Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iCAR-ILC-N101
- Development stage
- Unknown
- Lead developer
- Kyoto University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intraperitoneal
01
Overview
iCAR-ILC-N101 is an investigational, off-the-shelf cell therapy composed of innate lymphoid cells (ILC) or natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs). These cells are genetically engineered to express a chimeric antigen receptor (CAR) specific for Glypican-3 (GPC3), a cell-surface protein frequently overexpressed in certain solid tumors, including ovarian clear cell carcinoma. Developed by researchers at Kyoto University with support from the Japan Agency for Medical Research and Development (AMED), iCAR-ILC-N101 is currently being evaluated in a Phase 1 clinical trial for patients with GPC3-positive advanced ovarian clear cell carcinoma (OCCC) and peritoneal dissemination. The therapy is administered via intraperitoneal injection to maximize local exposure to tumor cells within the peritoneal cavity, leveraging the innate cytotoxic potential of ILC/NK cells combined with the targeted specificity of the CAR construct.
- Other names
- GPC3-CAR iPSC-derived ILC/NK therapy
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on iCAR-ILC-N101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCAR-ILC-N101.